glp-1 receptor agonists in idiopathic intracranial hypertension may improve outcomes GLP-1s may manage idiopathic intracranial
Description
Subgroup analyses showed no significant interactions for the six-composite end point across 12 prespecified clinical and demographic subgroups except for a marginal interaction for BMI subgroups
doi: 10.1056/NEJMoa2107519 72 LudvikBGiorginoFJdarEFriasJPFernndez LandLBrownKet al
2.3 Neuroinflammation and cognitive dysfunction in diabetes Diabetes, as a chronic metabolic disorder, induces a chronic inflammatory state that damages the central nervous system
The studied GLP-1 RAs included exenatide [14, 35, 37, 39], liraglutide [27, 36,37,38,39], semaglutide [27, 34, 37,38,39], lixisenatide [37, 39], dulaglutide [37, 39], albiglutide [39] and the dual agonist (GLP-1 and Glucose-dependent insulinotropic polypeptide (GIP)) tirzepatide [29, 37]
PLoS One 11 , e0148827 (2016)
